Seelaus Asset Management LLC Decreases Holdings in Avantor, Inc. (NYSE:AVTR)

Seelaus Asset Management LLC lowered its stake in shares of Avantor, Inc. (NYSE:AVTR) by 22.2% in the fourth quarter, Holdings Channel reports. The firm owned 9,505 shares of the company’s stock after selling 2,710 shares during the period. Seelaus Asset Management LLC’s holdings in Avantor were worth $200,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Hantz Financial Services Inc. increased its stake in Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock worth $644,000 after buying an additional 503 shares in the last quarter. Blue Trust Inc. raised its stake in Avantor by 6.9% in the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after purchasing an additional 522 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Avantor by 0.5% in the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after purchasing an additional 542 shares in the last quarter. Veracity Capital LLC boosted its stake in Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after purchasing an additional 543 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after buying an additional 625 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on AVTR. Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Wells Fargo & Company decreased their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Raymond James dropped their price target on Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Barclays lifted their price objective on Avantor from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, UBS Group restated a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.46.

Avantor Stock Performance

Shares of AVTR stock opened at $19.15 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm has a market cap of $13.03 billion, a P/E ratio of 41.63, a P/E/G ratio of 3.87 and a beta of 1.28. The firm’s 50 day moving average price is $21.73 and its 200-day moving average price is $23.44. Avantor, Inc. has a one year low of $19.08 and a one year high of $28.00.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter last year, the company earned $0.22 earnings per share. As a group, equities research analysts predict that Avantor, Inc. will post 0.98 EPS for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.